NovaDigm Therapeutics

Release Summary

NovaDigm announces awards totaling $6 million from U.S. DoD to conduct clinical study of NDV-3A in military personnel at high risk for skin/soft tissue infections due to S. aureus, including MRSA.

NovaDigm Therapeutics